Trident Lifeline Limited has submitted the unaudited financial result (Standalone and consolidated) for the quarter ended June 30,2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Trident Lifeline Limited reported its unaudited Q1 FY26 results on July 28, 2025. On a standalone basis, total income rose to ₹1,935.48 lakhs from ₹1,520.96 lakhs in Q1 FY25, a growth of about 27% year-on-year. Net profit for the quarter stood at ₹347.59 lakhs (up from ₹301.26 lakhs in Q1 FY25), with basic and diluted EPS of ₹3.02 versus ₹2.02 earlier. On a consolidated basis (including subsidiaries TNS Pharma, TLL Parenterals, TLL Elements, Trident Mediquip and TLL Herbal), total income was ₹2,495.90 lakhs and net profit was ₹306.28 lakhs. The auditor (A Bafna & Associates) issued an unqualified limited review report with no qualifications. The board also appointed M/s. Amareliya & Associates as Secretarial Auditor for an initial 5-year term (FY 2025-26 to FY 2029-30), subject to shareholder approval.
Strong revenue growth on the standalone side and a clean audit report are positive signals, though profit growth of around 15% lagged the revenue jump, suggesting some margin pressure. The new Secretarial Auditor appointment is routine governance housekeeping.